APIMEDS PHARMACEUTICALS US, INC. Financing Cash Flow
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Financing Cash Flow of $4.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- APIMEDS PHARMACEUTICALS US, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $3.47M, a 70.77% decline year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $920.00K, a 244.31% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $8.49M, a 11001.54% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. net cash provided by (used in) financing activities for fiscal 2025 was $20.62M, a 6215.26% increase from fiscal 2024.
- APIMEDS PHARMACEUTICALS US, INC. net cash provided by (used in) financing activities for fiscal 2024 was $326.50K, a 68.37% decline from fiscal 2023.
- APIMEDS PHARMACEUTICALS US, INC. net cash provided by (used in) financing activities for fiscal 2023 was $1.03M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $4.39M 10-Q · filed 2026-08-14 | $12.88M derived: sum of 3 quarters · filed 2026-08-14 | $12.88M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $920.00K 10-Q · filed 2026-05-26 | $9.41M derived: sum of 2 quarters · filed 2026-05-26 | $9.41M derived: sum of 3 quarters · filed 2026-05-26 | $21.27M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $8.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | $8.49M derived: sum of 2 quarters · filed 2026-05-04 | $20.35M derived: sum of 3 quarters · filed 2026-08-14 | $20.62M 10-K · filed 2026-05-04 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $11.86M derived: sum of 2 quarters · filed 2026-08-14 | $12.13M 10-Q · filed 2025-11-12 | $12.20M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $11.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $12.13M 10-Q · filed 2026-08-14 | $12.20M derived: sum of 3 quarters · filed 2026-08-14 | $12.35M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $267.20K 10-Q · filed 2026-05-26 | $343.70K derived: sum of 2 quarters · filed 2026-05-26 | $493.70K derived: sum of 3 quarters · filed 2026-05-26 | |
| 2024-12-31 | $76.50K derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | $226.50K derived: sum of 2 quarters · filed 2026-05-04 | $326.50K 10-K · filed 2026-05-04 | |
| 2024-09-30 | $150.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $250.00K 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $100.00K 10-Q · filed 2025-08-19 | |||
| 2023-12-31 | $1.03M 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |